This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ECLIPSE was a completed clinical study designed to longitudinally evaluate chronic obstructive pulmonary disease and identify new patient subtypes and endpoints for COPD over a 3-year period.
| Feature | ECLIPSE |
|---|---|
| NCT ID | NCT00292552 |
| Status | Completed |
| Condition | Pulmonary Disease, Chronic Obstructive |
| Sponsor | GlaxoSmithKline |
| Sponsor type | Industry |
| Intervention | Novel endpoint determination (other) |
2. Clinical Question
The central scientific question of ECLIPSE was how longitudinal clinical measurements could be used to identify new patient subtypes and endpoints relevant to chronic obstructive pulmonary disease.
Population
Participants with chronic obstructive pulmonary disease enrolled in a longitudinal evaluation study.
Intervention
Novel endpoint determination (other).
Comparator
The registry identifies 3 study arms but does not report arm-specific comparator descriptions.
Primary question
Can longitudinal assessment identify new COPD patient subtypes and predictive endpoints?
3. Trial Design
4. Primary Endpoint
| Endpoint | Definition / Time Frame |
|---|---|
| Identifying new patient subtypes and endpoints for COPD | 3 years |
The primary endpoint reflects a methodological goal rather than a conventional treatment-comparison endpoint. Studies focused on biomarker discovery, phenotyping, and endpoint development often require statistical approaches that integrate repeated measurements, patient characteristics, and longitudinal disease trajectories.
5. Planned Analysis
The registry reports the primary endpoint that was measured over 3 years but does not report posted statistical analyses or endpoint results on ClinicalTrials.gov.
For a longitudinal COPD endpoint-identification study, analyses would typically involve methods capable of evaluating changes over time, identifying patterns among patients, and assessing whether measured characteristics can distinguish clinically meaningful patient subtypes. Depending on the prespecified statistical plan, approaches may include longitudinal models, clustering methods, or predictive modeling frameworks.
Longitudinal studies differ from simple cross-sectional comparisons because the statistical objective is often to understand patterns of change rather than a single measurement at one time point.
6. Statistical Methodology
Longitudinal analysis
Measurements collected repeatedly over time require statistical methods that account for correlation within the same participant. Observations from one individual are generally not independent because they share underlying patient characteristics.
Patient subtype identification
Identifying patient subtypes is a classification problem. Statistical approaches may examine whether groups of participants demonstrate distinct patterns of disease characteristics or progression.
Surrogate endpoint development
A predictive surrogate endpoint is intended to provide information about future clinical outcomes. Establishing useful surrogate endpoints requires more than identifying an association; the relationship between the candidate endpoint and clinically relevant outcomes must be carefully evaluated.
A biomarker or measurement can correlate with disease progression without necessarily replacing a clinical endpoint in future trials.
7. Statistical Methods Explained
Why are longitudinal measurements important?
COPD is a chronic condition where disease characteristics may change over time. Repeated observations can reveal patterns that are not visible from a single baseline measurement.
Why identify patient subtypes?
Patients with the same diagnosis may have different disease trajectories. Statistical classification methods can help describe variation within a disease population.
Why are surrogate endpoints difficult to establish?
A surrogate endpoint must provide reliable information about clinically meaningful outcomes. A measurement that changes with disease does not automatically predict treatment effects on patient outcomes.
What makes longitudinal analysis different from a simple comparison?
Longitudinal methods account for repeated observations and focus on individual patterns of change over time.
Why is validation important for predictive endpoints?
Candidate endpoints require evaluation beyond discovery because patterns observed in one dataset may not generalize to other populations.
8. Limitations
- Posted results: The ClinicalTrials.gov record does not report statistical analyses or endpoint results.
- Endpoint complexity: Identifying COPD subtypes and predictive endpoints involves methodological challenges beyond estimating a single treatment effect.
- Generalizability: The applicability of identified subtypes depends on the characteristics of the studied population.
- Validation: Candidate surrogate endpoints require additional evidence before they can replace traditional clinical outcomes.
- Statistical model dependence: Classification and prediction results can depend on the statistical methods and assumptions used.
9. Why This Trial Matters Statistically
ECLIPSE is an important example of a clinical research problem where the statistical objective is not only comparing treatments but understanding disease heterogeneity and improving measurement strategies.
| Concept | How it appears in ECLIPSE |
|---|---|
| Longitudinal data | Three-year evaluation of COPD characteristics over time |
| Patient heterogeneity | Identification of new COPD patient subtypes |
| Endpoint development | Evaluation of predictive surrogate endpoints |
| Prediction | Searching for measurements associated with future disease patterns |
| Clinical measurement | Improving understanding of COPD progression |
10. Sources
- ClinicalTrials.gov: NCT00292552.
Continue through the Clinical Biostats knowledge graph
Explore clinical trial methods, statistical concepts, and analysis workflows.